Literature DB >> 17522387

Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

J J Halperin1, E D Shapiro, E Logigian, A L Belman, L Dotevall, G P Wormser, L Krupp, G Gronseth, C T Bever.   

Abstract

OBJECTIVE: To provide evidence-based recommendations on the treatment of nervous system Lyme disease and post-Lyme syndrome. Three questions were addressed: 1) Which antimicrobial agents are effective? 2) Are different regimens preferred for different manifestations of nervous system Lyme disease? 3) What duration of therapy is needed?
METHODS: The authors analyzed published studies (1983-2003) using a structured review process to classify the evidence related to the questions posed.
RESULTS: The panel reviewed 353 abstracts which yielded 112 potentially relevant articles that were reviewed, from which 37 articles were identified that were included in the analysis.
CONCLUSIONS: There are sufficient data to conclude that, in both adults and children, this nervous system infection responds well to penicillin, ceftriaxone, cefotaxime, and doxycycline (Level B recommendation). Although most studies have used parenteral regimens for neuroborreliosis, several European studies support use of oral doxycycline in adults with meningitis, cranial neuritis, and radiculitis (Level B), reserving parenteral regimens for patients with parenchymal CNS involvement, other severe neurologic symptomatology, or failure to respond to oral regimens. The number of children (> or =8 years of age) enrolled in rigorous studies of oral vs parenteral regimens has been smaller, making conclusions less statistically compelling. However, all available data indicate results are comparable to those observed in adults. In contrast, there is no compelling evidence that prolonged treatment with antibiotics has any beneficial effect in post-Lyme syndrome (Level A).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17522387     DOI: 10.1212/01.wnl.0000265517.66976.28

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  58 in total

1.  Lyme disease in Canada: Q & A for paediatricians.

Authors: 
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

2.  Lyme disease in Canada: Q & A for paediatricians.

Authors: 
Journal:  Paediatr Child Health       Date:  2009-02       Impact factor: 2.253

3.  Lyme Neuroborreliosis.

Authors:  Sebastian Rauer; Stefan Kastenbauer; Volker Fingerle; Klaus-Peter Hunfeld; Hans-Iko Huppertz; Rick Dersch
Journal:  Dtsch Arztebl Int       Date:  2018-11-09       Impact factor: 5.594

Review 4.  Lyme Neuroborreliosis: Clinical Outcomes, Controversy, Pathogenesis, and Polymicrobial Infections.

Authors:  Juan Carlos Garcia-Monco; Jorge L Benach
Journal:  Ann Neurol       Date:  2019-01       Impact factor: 10.422

Review 5.  [Bacterial infections of the central nervous system].

Authors:  M Klein; H-W Pfister
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

Review 6.  Chronic Lyme disease.

Authors:  Paul M Lantos
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

7.  Treatment-Related Complications in Children Hospitalized With Disseminated Lyme Disease.

Authors:  Christine Chang; Kristen A Feemster; Susan Coffin; Lori K Handy
Journal:  J Pediatric Infect Dis Soc       Date:  2017-09-01       Impact factor: 3.164

8.  Proof that chronic lyme disease exists.

Authors:  Daniel J Cameron
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-05-25

9.  The Infectious Diseases Society of America Lyme guidelines: a cautionary tale about the development of clinical practice guidelines.

Authors:  Lorraine Johnson; Raphael B Stricker
Journal:  Philos Ethics Humanit Med       Date:  2010-06-09       Impact factor: 2.464

10.  A case of Lyme neuroborreliosis with bilateral recurrent laryngeal nerve palsy.

Authors:  M Furtner; M Patjas; B Frauscher; E Schmutzhard; J Willeit
Journal:  JRSM Short Rep       Date:  2010-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.